A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
about
Mitoxantrone for multiple sclerosisOptimizing treatment success in multiple sclerosisTherapeutic decisions in multiple sclerosis: moving beyond efficacyValidity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortexPrevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional studyEfficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelinationTargeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapiesRegulation of Th1 cells and experimental autoimmune encephalomyelitis by glycogen synthase kinase-3.Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: differential expression of neurotrophic and gliotrophic factorsTreatment update in multiple sclerosis.Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.Methods and measures: what's new for MS?The role of natural killer cells in multiple sclerosis and their therapeutic implications.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signalingMultiple sclerosis: combination therapy in MS--still a valid strategy.Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.Astrocytes regulate myelin clearance through recruitment of microglia during cuprizone-induced demyelination.In vivo conversion of astrocytes to myelinating cells by miR-302/367 and valproate to enhance myelin repair.Clinical trials in multiple sclerosis: milestones
P2860
Q24202866-84510B6D-F777-4501-9FA1-A99C826D27C6Q26771968-49A0A466-D243-411E-A96F-1835E7BDA3C6Q28541039-CF00AFF9-00FE-4688-8301-626CA56C50C6Q33605353-EDC851D9-0D70-4998-9BDC-ECC96B6A5EAFQ33930225-95A6A20C-0777-491D-BF35-711AFE5908BBQ33931512-FAE6C725-44F2-48C9-8CDF-ECAE918604FDQ34543420-EE79F190-3B7C-40D4-B160-33F8A594066DQ35019187-2EDEF687-DE6F-45C3-9455-88FE9ABD8B6DQ35276622-FF2C2508-88A1-4D32-AC26-897CD45AE084Q35949316-D8D835D4-8051-47FA-A7E3-DFE94EFC92C1Q36066728-81C5CE0A-9378-4412-84F6-ECE03484DAC1Q36401237-22A17B6E-64DC-4FB2-9622-2F73E6CD7DD0Q36437015-69B30D5C-E208-493B-84D9-7EA79D16E426Q36863419-A97EAFBF-B3C9-4048-9D2D-FC39B3C0BC59Q37161098-5D07F5EF-1D78-4E28-9085-C247519FB24CQ37996859-A5175103-CDBE-4834-8CB9-84298366D35AQ37997089-4CA9358A-1C1A-4E56-ADC4-3B8DD155259DQ38069035-6BB25FD4-595B-47B4-8027-8CC15E42C809Q38089599-CCA24CEA-9F39-4465-881C-FFE7B4B49BCDQ38101003-623B6FF7-0646-44E6-83A8-12B2B994D696Q41845688-E5A0AFED-D4DB-4BB7-B682-80CC2AA889F3Q43704412-B334765B-A04F-4019-8BF9-119635417352Q44550327-17FAE627-FC1F-44EE-9627-D5F9AEB40E38Q45757461-AA65D245-E723-4EB2-BC30-7C7551FB4FE7Q48337396-442CB014-E82F-49A3-AF25-797819BFB147Q57176820-F882DA0C-0B83-40DA-ABD5-73B6C62ACB4D
P2860
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@en
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@nl
type
label
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@en
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@nl
prefLabel
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@en
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@nl
P2860
P356
P1476
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
@en
P2860
P2888
P304
P356
10.1038/NRNEUROL.2011.41
P407
P577
2011-04-05T00:00:00Z